Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen F Madden

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Oncotarget|October 25, 2016
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancerSinead Toomey, Stephen F Madden, Simon J Furney, et al.
Thorax|October 24, 2020
Use of exhaled breath condensate (EBC) in the diagnosis of SARS-COV-2 (COVID-19)Daniel J Ryan, Sinead Toomey, Stephen F Madden, et al.
The FEBS Journal|June 23, 2015
Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patientsFiona Lanigan, Gerard L Brien, Yue Fan, et al.
Acta Oncologica (Stockholm, Sweden)|June 5, 2025
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysisJohn Crown, Alex J Eustace, Denis M Collins, et al.
NPJ Breast Cancer|September 27, 2023
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancerNicola Cosgrove, Alex J Eustace, Peter O'Donovan, et al.
BMC Cancer|October 12, 2018
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAILAlex J Eustace, Neil T Conlon, Martina S J McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2019
BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast CancerLouise Walsh, Kathryn E Haley, Bruce Moran, et al.
Breast Cancer Research : BCR|July 29, 2017
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapiesSinead Toomey, Alexander J Eustace, Joanna Fay, et al.
Cancer Research|April 30, 2017
Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast CancerBo Li, Triona Ni Chonghaile, Yue Fan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2020
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast CancerDenis M Collins, Stephen F Madden, Nicola Gaynor, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Oncotarget|October 25, 2016
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancerSinead Toomey, Stephen F Madden, Simon J Furney, et al.
Thorax|October 24, 2020
Use of exhaled breath condensate (EBC) in the diagnosis of SARS-COV-2 (COVID-19)Daniel J Ryan, Sinead Toomey, Stephen F Madden, et al.
The FEBS Journal|June 23, 2015
Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patientsFiona Lanigan, Gerard L Brien, Yue Fan, et al.
Acta Oncologica (Stockholm, Sweden)|June 5, 2025
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysisJohn Crown, Alex J Eustace, Denis M Collins, et al.
NPJ Breast Cancer|September 27, 2023
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancerNicola Cosgrove, Alex J Eustace, Peter O'Donovan, et al.
BMC Cancer|October 12, 2018
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAILAlex J Eustace, Neil T Conlon, Martina S J McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2019
BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast CancerLouise Walsh, Kathryn E Haley, Bruce Moran, et al.
Breast Cancer Research : BCR|July 29, 2017
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapiesSinead Toomey, Alexander J Eustace, Joanna Fay, et al.
Cancer Research|April 30, 2017
Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast CancerBo Li, Triona Ni Chonghaile, Yue Fan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2020
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast CancerDenis M Collins, Stephen F Madden, Nicola Gaynor, et al.
Pageof 8